Skip to main content

Table 1 Patient’s BMI, chemotherapy doses given and performance status

From: From palliative to curative treatment - stage IV mucinous adenocarcinoma, successfully treated with metronomic capecitabine in combination with Bevacizumab and surgery- a case report

Year

Month

BMI

Treatment

Dose

Performance status

2011

 

31.2

   

2013

Feb

29.4

FLOX C1

Oxaliplatin: 150 mg Fluorouracil: 950 mg Calciumfolinat: 110 mg

0

 

March

28.7

FLOX C2

Oxaliplatin: 140 mg Fluorouracil: 900 mg Calciumfolinat: 100 mg

1

 

April

27.8

FLOX C3

Oxaliplatin: 120 mg Fluorouracil: 720 mg Calciumfolinat: 100 mg

1

 

June

29.2

Capecitabine

500mgx1

1-2

 

July

 

Capecitabine/ Bevacizumab C1

500 mg × 2/ 350 mg

1-2

 

Aug

 

Capecitabine/ Bevacizumab C2

500 mg × 2/ 350 mg

0-1

   

Capecitabine/ Bevacizumab C3

500 mg × 2/ 350 mg

 
 

Sept

 

Capecitabine/ Bevacizumab C4

500 mg × 2/ 350 mg

 
   

Capecitabine/ Bevacizumab C5

500 mg × 2/ 350 mg

 
 

Oct

29.8

Capecitabine/ Bevacizumab C6

500 mg × 2/ 350 mg

0-1

   

Capecitabine/ Bevacizumab C7

500 mg × 2/ 350 mg

 

2014

Jan

31.2

  

0